Primaquine

Malaria, prophylaxis of Malaria, Malaria + 3 more
Treatment
3 FDA approvals
20 Active Studies for Primaquine

What is Primaquine

PrimaquineThe Generic name of this drug
Treatment SummaryAn aminoquinoline, chloroquine is an oral medication used to completely cure malaria caused by either the vivax or ovale parasite. It can also be used to prevent the transmission of falciparum malaria by people traveling to areas where the disease is present. Common side effects of chloroquine include anemia and gastrointestinal issues.
Primaquine Phosphateis the brand name
Primaquine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Primaquine Phosphate
Primaquine
2011
14

Approved as Treatment by the FDA

Primaquine, also known as Primaquine Phosphate, is approved by the FDA for 3 uses such as Malaria caused by Plasmodium ovale and Malaria .
Malaria caused by Plasmodium ovale
Malaria
Malaria

Effectiveness

How Primaquine Affects PatientsPrimaquine is a medication used to treat malaria. It works by interrupting a part of the malaria parasite that provides it with energy, which stops the infection and allows the person to recover. Primaquine is not used for prevention, only for treatment. It kills the intrahepatic form of malaria and stops relapses from occurring. It also kills all forms of malaria parasites, but is always used with another medication (called a blood schizonticide) and never alone. Primaquine can also stop the spread of malaria by killing gametocytes.
How Primaquine works in the bodyPrimaquine works by either creating oxygen molecules in the body or disrupting the electron transport of parasites. It is also thought to affect how protozoal DNA works.

When to interrupt dosage

The measure of Primaquine is contingent upon the diagnosed problem, including Malaria, prophylaxis of Malaria and Malaria brought about by Plasmodium ovale. The quantity of dosage is determined by the method of administration (e.g. Tablet, film coated - Oral or Oral) recorded in the table underneath.
Condition
Dosage
Administration
Pneumonia, Pneumocystis
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
HIV
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Malaria
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
prophylaxis of Malaria
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Malaria
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Malaria
, 26.3 mg, 15.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Primaquine has eight contraindications, thus it should not be utilized when experiencing any of the conditions enumerated in the table below.Primaquine Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Systemic Diseases
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
hemolytic agents
Do Not Combine
Lupus Erythematosus
Do Not Combine
Acute Coryza
Do Not Combine
There are 20 known major drug interactions with Primaquine.
Common Primaquine Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Primaquine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Primaquine.
Acepromazine
Major
The risk or severity of QTc prolongation can be increased when Primaquine is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of QTc prolongation can be increased when Primaquine is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of QTc prolongation can be increased when Primaquine is combined with Acetophenazine.

Primaquine Novel Uses: Which Conditions Have a Clinical Trial Featuring Primaquine?

123 active studies are investigating the novel utilization of Primaquine to treat HIV, Malaria and Pneumocystis Jirovecii Pneumonia.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
prophylaxis of Malaria
0 Actively Recruiting
Malaria
0 Actively Recruiting
Malaria
0 Actively Recruiting
Malaria
0 Actively Recruiting
Pneumonia, Pneumocystis
1 Actively Recruiting
Phase 3

Patient Q&A Section about primaquine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the side effect of primaquine?

"You may experience nausea, vomiting, dizziness, stomach upset, and abdominal cramps. If any of these symptoms persist or worsen, tell your doctor or pharmacist."

Answered by AI

Is primaquine an antibiotic?

"Primaquine is an antibiotic used to treat various types of infections. It can be co-administered with clindamycin for the treatment of Pneumocystis carinii pneumonia (PCP)."

Answered by AI

Why primaquine is given for 14 days?

"Plasmodium vivax infections are a major problem worldwide when it comes to malaria. The World Health Organization recommends a 14-day course of primaquine in order to get rid of the liver stage of the parasite and prevent the disease from coming back."

Answered by AI

Is primaquine the same as chloroquine?

"Chloroquine is an effective drug against the asexual stages of the parasite, while primaquine is less effective but is the only drug that kills the dormant liver stage parasites and prevents relapse."

Answered by AI

Clinical Trials for Primaquine

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Primaquine clinical trials? We made a collection of clinical trials featuring Primaquine, we think they might fit your search criteria.Go to Trials
Have you considered Primaquine clinical trials? We made a collection of clinical trials featuring Primaquine, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Primaquine clinical trials? We made a collection of clinical trials featuring Primaquine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security